Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report

Hideyuki Niwa; Sakiko Otani; Norihiro Nakada; Jiichiro Sasaki; Hideo Saka; Noriyuki Masuda

doi:10.1016/j.rmcr.2018.01.006

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report

Hideyuki Niwa, Sakiko Otani, Norihiro Nakada, Jiichiro Sasaki, Hideo Saka, Noriyuki Masuda

Research output: Contribution to journal › Article › peer-review

Abstract

Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTX + CBDCA for treating carcinosarcoma with ILD.

Original language	English
Pages (from-to)	131-135
Number of pages	5
Journal	Respiratory Medicine Case Reports
Volume	23
DOIs	https://doi.org/10.1016/j.rmcr.2018.01.006
Publication status	Published - 2018
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.rmcr.2018.01.006

Cite this

@article{ae1df331d1f64aadad2bb4bf104b10b5,

title = "Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report",

abstract = "Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTX + CBDCA for treating carcinosarcoma with ILD.",

author = "Hideyuki Niwa and Sakiko Otani and Norihiro Nakada and Jiichiro Sasaki and Hideo Saka and Noriyuki Masuda",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

doi = "10.1016/j.rmcr.2018.01.006",

language = "English",

volume = "23",

pages = "131--135",

journal = "Respiratory Medicine Case Reports",

issn = "2213-0071",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease

T2 - A case report

AU - Niwa, Hideyuki

AU - Otani, Sakiko

AU - Nakada, Norihiro

AU - Sasaki, Jiichiro

AU - Saka, Hideo

AU - Masuda, Noriyuki

PY - 2018

Y1 - 2018

N2 - Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTX + CBDCA for treating carcinosarcoma with ILD.

AB - Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTX + CBDCA for treating carcinosarcoma with ILD.

UR - http://www.scopus.com/inward/record.url?scp=85042918622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042918622&partnerID=8YFLogxK

U2 - 10.1016/j.rmcr.2018.01.006

DO - 10.1016/j.rmcr.2018.01.006

M3 - Article

AN - SCOPUS:85042918622

SN - 2213-0071

VL - 23

SP - 131

EP - 135

JO - Respiratory Medicine Case Reports

JF - Respiratory Medicine Case Reports

ER -

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this